Key result
Dabuzalgron prevents doxorubicin-induced cardiac dysfunction and reduces myocardial fibrosis in preclinical cardiotoxicity.
Why the study?
Novel cancer therapies are associated with cardiovascular complications, creating a major clinical need for cardio-oncology to understand and prevent cardiotoxicity.
[Figure: see text] [Figure: see text]
No takes yet. Share an insight, caveat, or question.
Moslehi et al. (2017) conducted an editorial in Doxorubicin-induced cardiotoxicity. Dabuzalgron was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: